PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study) - Trial NCT05763602
Access comprehensive clinical trial information for NCT05763602 through Pure Global AI's free database. This Phase 4 trial is sponsored by Loreen Herwaldt and is currently Recruiting. The study focuses on Surgical Site Infection. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Loreen Herwaldt
University of Iowa
Timeline & Enrollment
Phase 4
Sep 15, 2022
May 31, 2025
Primary Outcome
Incidence of Complex (deep incisional or organ space) Staphylococcus aureus surgical site infection (SSI)
Summary
The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of
 patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of
 high-energy lower extremity fractures (HELEF) will decrease the patients' risk of surgical
 site infections (SSI), particularly those caused by Staphylococcus aureus.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05763602
Non-Device Trial